array(40) {
  [0]=>
  string(4) "2677"
  ["article_id"]=>
  string(4) "2677"
  [1]=>
  string(104) "Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries)"
  ["article_title"]=>
  string(104) "Quality and GMP Compliance for Virtual Companies (Pharmaceutical, Medical Device & Biologics Industries)"
  [2]=>
  string(150) "In this two day workshop conference you will learn the requirements and expectations of major health care regulators that are applicable to "virt"
  ["short_description"]=>
  string(150) "In this two day workshop conference you will learn the requirements and expectations of major health care regulators that are applicable to "virt"
  [3]=>
  string(526) "In this two day workshop conference you will learn the requirements and expectations of major health care regulators that are applicable to "virtual" companies. You will learn how to diagnose your company's needs based on which GMP and GCP-governed operations you retain and which you outsource; what the current expectations and best industry practices are for selecting, qualifying and monitoring your contractors to ensure they are meeting your requirements; and how to build a quality system fram…"
  ["description"]=>
  string(526) "In this two day workshop conference you will learn the requirements and expectations of major health care regulators that are applicable to "virtual" companies. You will learn how to diagnose your company's needs based on which GMP and GCP-governed operations you retain and which you outsource; what the current expectations and best industry practices are for selecting, qualifying and monitoring your contractors to ensure they are meeting your requirements; and how to build a quality system fram…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(148) "
https://www.pharmiweb.com/event/quality-and-gmp-compliance-for-virtual-companies-pharmaceutical-medical-device-biologics-industries                "
  ["blog_url"]=>
  string(148) "
https://www.pharmiweb.com/event/quality-and-gmp-compliance-for-virtual-companies-pharmaceutical-medical-device-biologics-industries                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:39"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2676"
  ["article_id"]=>
  string(4) "2676"
  [1]=>
  string(75) "Designing and Sustaining New and Existing Product Stability Testing Program"
  ["article_title"]=>
  string(75) "Designing and Sustaining New and Existing Product Stability Testing Program"
  [2]=>
  string(150) "This seminar will provide a great resource to Pharmaceutical, Biotechnology, Diagnostics, Cell Therapy, Drugs, Biologics, OTC, Radio-pharmaceutical, P"
  ["short_description"]=>
  string(150) "This seminar will provide a great resource to Pharmaceutical, Biotechnology, Diagnostics, Cell Therapy, Drugs, Biologics, OTC, Radio-pharmaceutical, P"
  [3]=>
  string(516) "This seminar will provide a great resource to Pharmaceutical, Biotechnology, Diagnostics, Cell Therapy, Drugs, Biologics, OTC, Radio-pharmaceutical, Pharmacies and Medical Device Industries in understanding the effective way to establish a new or modified product stability testing program. This program is an important part of a product's regulatory filing requirements as well as the determination of the shelf life or expiration date of the product. This is an important part of every business fin…"
  ["description"]=>
  string(516) "This seminar will provide a great resource to Pharmaceutical, Biotechnology, Diagnostics, Cell Therapy, Drugs, Biologics, OTC, Radio-pharmaceutical, Pharmacies and Medical Device Industries in understanding the effective way to establish a new or modified product stability testing program. This program is an important part of a product's regulatory filing requirements as well as the determination of the shelf life or expiration date of the product. This is an important part of every business fin…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(124) "
https://www.pharmiweb.com/event/designing-and-sustaining-new-and-existing-product-stability-testing-program                "
  ["blog_url"]=>
  string(124) "
https://www.pharmiweb.com/event/designing-and-sustaining-new-and-existing-product-stability-testing-program                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:39"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2675"
  ["article_id"]=>
  string(4) "2675"
  [1]=>
  string(79) "11th International Conference and Exhibition on Pharmacovigilance & Drug Safety"
  ["article_title"]=>
  string(79) "11th International Conference and Exhibition on Pharmacovigilance & Drug Safety"
  [2]=>
  string(150) "The gathering will address Pharmaceutical Research in the area of Pharmacovigilance and Drug Safety, while laying emphasis on innovative methodologies"
  ["short_description"]=>
  string(150) "The gathering will address Pharmaceutical Research in the area of Pharmacovigilance and Drug Safety, while laying emphasis on innovative methodologies"
  [3]=>
  string(527) "The gathering will address Pharmaceutical Research in the area of Pharmacovigilance and Drug Safety, while laying emphasis on innovative methodologies in pharmaceutical and Drug Safety.  Pharmacovigilance 2018 will be the best venue for Research Associate, Research Scientist, Directors, CEO’s of Pharmaceutical Organizations, Drug Delivery Technology Manufacturers, Regulatory Affairs Associate, Bio Statistician, Health professionals, Scholars from Pharmaceutical backgrounds, Quality Con…"
  ["description"]=>
  string(527) "The gathering will address Pharmaceutical Research in the area of Pharmacovigilance and Drug Safety, while laying emphasis on innovative methodologies in pharmaceutical and Drug Safety.  Pharmacovigilance 2018 will be the best venue for Research Associate, Research Scientist, Directors, CEO’s of Pharmaceutical Organizations, Drug Delivery Technology Manufacturers, Regulatory Affairs Associate, Bio Statistician, Health professionals, Scholars from Pharmaceutical backgrounds, Quality Con…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(126) "
https://www.pharmiweb.com/event/11th-international-conference-and-exhibition-on-pharmacovigilance-drug-safety                "
  ["blog_url"]=>
  string(126) "
https://www.pharmiweb.com/event/11th-international-conference-and-exhibition-on-pharmacovigilance-drug-safety                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:39"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2674"
  ["article_id"]=>
  string(4) "2674"
  [1]=>
  string(19) "Child Congress 2019"
  ["article_title"]=>
  string(19) "Child Congress 2019"
  [2]=>
  string(168) "Invitation of Child Congress 2019 in Beijing, China.&#nl&#nl &#nl&#nlChild Congress 2019&#nl&#nlTheme: Infant & Adolescent Health: Congregating Diversi"
  ["short_description"]=>
  string(168) "Invitation of Child Congress 2019 in Beijing, China.&#nl&#nl &#nl&#nlChild Congress 2019&#nl&#nlTheme: Infant & Adolescent Health: Congregating Diversi"
  [3]=>
  string(548) "Invitation of Child Congress 2019 in Beijing, China.&#nl&#nl &#nl&#nlChild Congress 2019&#nl&#nlTheme: Infant & Adolescent Health: Congregating Diversities&#nl&#nlLexis Conferences invites all the participants from all over the world to attend “Child Congress 2019” during June 21-22, 2019 Beijing, China which includes prompt keynote presentations, special sessions, workshops, symposiums, oral talks, poster presentations and exhibitions. Please join us in this family-friendly venue to find ways to add t…"
  ["description"]=>
  string(548) "Invitation of Child Congress 2019 in Beijing, China.&#nl&#nl &#nl&#nlChild Congress 2019&#nl&#nlTheme: Infant & Adolescent Health: Congregating Diversities&#nl&#nlLexis Conferences invites all the participants from all over the world to attend “Child Congress 2019” during June 21-22, 2019 Beijing, China which includes prompt keynote presentations, special sessions, workshops, symposiums, oral talks, poster presentations and exhibitions. Please join us in this family-friendly venue to find ways to add t…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(70) "
https://www.pharmiweb.com/event/child-congress-2019-1                "
  ["blog_url"]=>
  string(70) "
https://www.pharmiweb.com/event/child-congress-2019-1                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:39"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2673"
  ["article_id"]=>
  string(4) "2673"
  [1]=>
  string(52) "Infant & Adolescent Health: Congregating Diversities"
  ["article_title"]=>
  string(52) "Infant & Adolescent Health: Congregating Diversities"
  [2]=>
  string(158) "Lexis Conferences invites all the participants from all over the world to attend “Child Congress 2019” during June 21-22, 2019 Beijing, China whic"
  ["short_description"]=>
  string(158) "Lexis Conferences invites all the participants from all over the world to attend “Child Congress 2019” during June 21-22, 2019 Beijing, China whic"
  [3]=>
  string(536) "Lexis Conferences invites all the participants from all over the world to attend “Child Congress 2019” during June 21-22, 2019 Beijing, China which includes prompt keynote presentations, special sessions, workshops, symposiums, oral talks, poster presentations and exhibitions. Please join us in this family-friendly venue to find ways to add to your day-to-day practice.&#nl&#nlFor more details visit: https://www.lexisconferences.com/child-congress&#nl&#nlFor other queries kindly let us know.&#nl&#nlPlease do…"
  ["description"]=>
  string(536) "Lexis Conferences invites all the participants from all over the world to attend “Child Congress 2019” during June 21-22, 2019 Beijing, China which includes prompt keynote presentations, special sessions, workshops, symposiums, oral talks, poster presentations and exhibitions. Please join us in this family-friendly venue to find ways to add to your day-to-day practice.&#nl&#nlFor more details visit: https://www.lexisconferences.com/child-congress&#nl&#nlFor other queries kindly let us know.&#nl&#nlPlease do…"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "3"
  ["category"]=>
  string(1) "3"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "58"
  ["rss_id"]=>
  string(2) "58"
  [14]=>
  string(98) "
https://www.pharmiweb.com/event/infant-adolescent-health-congregating-diversities                "
  ["blog_url"]=>
  string(98) "
https://www.pharmiweb.com/event/infant-adolescent-health-congregating-diversities                "
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:24:39"
  ["create_at"]=>
  string(19) "2019-05-23 14:24:39"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2582"
  ["article_id"]=>
  string(4) "2582"
  [1]=>
  string(81) "Thermo Fisher Scientific to acquire manufacturing site in Cork, Ireland, from GSK"
  ["article_title"]=>
  string(81) "Thermo Fisher Scientific to acquire manufacturing site in Cork, Ireland, from GSK"
  [2]=>
  string(150) "The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredien"
  ["short_description"]=>
  string(150) "The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredien"
  [3]=>
  string(627) "
The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs). With more than 400 employees, the 
&#nl
The post Thermo Fisher Scientific to acquire manufacturing site in Cork, Ireland, from GSK appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(627) "
The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex active pharmaceutical ingredients (APIs). With more than 400 employees, the 
&#nl
The post Thermo Fisher Scientific to acquire manufacturing site in Cork, Ireland, from GSK appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(132) "https://www.pharmaceutical-business-review.com/news/thermo-fisher-scientific-to-acquire-manufacturing-site-in-cork-ireland-from-gsk/"
  ["blog_url"]=>
  string(132) "https://www.pharmaceutical-business-review.com/news/thermo-fisher-scientific-to-acquire-manufacturing-site-in-cork-ireland-from-gsk/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:59"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2580"
  ["article_id"]=>
  string(4) "2580"
  [1]=>
  string(45) "Ligand licenses VER250840 to Cumulus Oncology"
  ["article_title"]=>
  string(45) "Ligand licenses VER250840 to Cumulus Oncology"
  [2]=>
  string(150) "Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and ti"
  ["short_description"]=>
  string(150) "Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and ti"
  [3]=>
  string(530) "
Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in 
&#nl
The post Ligand licenses VER250840 to Cumulus Oncology appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(530) "
Under the terms of the agreement, Ligand will receive an upfront license fee, and is eligible to receive over $76 million of milestone payments and tiered royalties in 
&#nl
The post Ligand licenses VER250840 to Cumulus Oncology appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(98) "https://www.pharmaceutical-business-review.com/news/ligand-licenses-ver250840-to-cumulus-oncology/"
  ["blog_url"]=>
  string(98) "https://www.pharmaceutical-business-review.com/news/ligand-licenses-ver250840-to-cumulus-oncology/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:59"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2581"
  ["article_id"]=>
  string(4) "2581"
  [1]=>
  string(66) "AbbVie stops phase 3 glioblastoma trial of Depatux-M over futility"
  ["article_title"]=>
  string(66) "AbbVie stops phase 3 glioblastoma trial of Depatux-M over futility"
  [2]=>
  string(150) "Depatux-M fails to meet objectives in INTELLANCE-1 study The biopharma company arrived at the decision after finding that the late-stage INTELLANCE-1 "
  ["short_description"]=>
  string(150) "Depatux-M fails to meet objectives in INTELLANCE-1 study The biopharma company arrived at the decision after finding that the late-stage INTELLANCE-1 "
  [3]=>
  string(562) "
Depatux-M fails to meet objectives in INTELLANCE-1 study The biopharma company arrived at the decision after finding that the late-stage INTELLANCE-1 study did not meet primary endpoint of 
&#nl
The post AbbVie stops phase 3 glioblastoma trial of Depatux-M over futility appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(562) "
Depatux-M fails to meet objectives in INTELLANCE-1 study The biopharma company arrived at the decision after finding that the late-stage INTELLANCE-1 study did not meet primary endpoint of 
&#nl
The post AbbVie stops phase 3 glioblastoma trial of Depatux-M over futility appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/abbvie-glioblastoma-trial-depatux-m/"
  ["blog_url"]=>
  string(88) "https://www.pharmaceutical-business-review.com/news/abbvie-glioblastoma-trial-depatux-m/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:59"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2579"
  ["article_id"]=>
  string(4) "2579"
  [1]=>
  string(61) "US FDA approves GATTEX for children with short bowel syndrome"
  ["article_title"]=>
  string(61) "US FDA approves GATTEX for children with short bowel syndrome"
  [2]=>
  string(150) "In children, SBS is a life-threatening, chronic, and rare malabsorption disorder resulting from surgical removal of a large portion of the intestine, "
  ["short_description"]=>
  string(150) "In children, SBS is a life-threatening, chronic, and rare malabsorption disorder resulting from surgical removal of a large portion of the intestine, "
  [3]=>
  string(603) "
In children, SBS is a life-threatening, chronic, and rare malabsorption disorder resulting from surgical removal of a large portion of the intestine, which is typically due to congenital 
&#nl
The post US FDA approves GATTEX for children with short bowel syndrome appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(603) "
In children, SBS is a life-threatening, chronic, and rare malabsorption disorder resulting from surgical removal of a large portion of the intestine, which is typically due to congenital 
&#nl
The post US FDA approves GATTEX for children with short bowel syndrome appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(136) "https://www.pharmaceutical-business-review.com/news/us-fda-approves-gattex-for-children-above-one-year-of-age-with-short-bowel-syndrome/"
  ["blog_url"]=>
  string(136) "https://www.pharmaceutical-business-review.com/news/us-fda-approves-gattex-for-children-above-one-year-of-age-with-short-bowel-syndrome/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:59"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2578"
  ["article_id"]=>
  string(4) "2578"
  [1]=>
  string(87) "AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma"
  ["article_title"]=>
  string(87) "AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma"
  [2]=>
  string(152) "These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Confer"
  ["short_description"]=>
  string(152) "These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Confer"
  [3]=>
  string(649) "
These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference. The trial compared Symbicort Turbuhaler with 
&#nl
The post AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(649) "
These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference. The trial compared Symbicort Turbuhaler with 
&#nl
The post AstraZeneca says Symbicort as anti-inflammatory reliever reduces attacks in mild asthma appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(140) "https://www.pharmaceutical-business-review.com/news/astrazeneca-says-symbicort-as-anti-inflammatory-reliever-reduces-attacks-in-mild-asthma/"
  ["blog_url"]=>
  string(140) "https://www.pharmaceutical-business-review.com/news/astrazeneca-says-symbicort-as-anti-inflammatory-reliever-reduces-attacks-in-mild-asthma/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:59"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2577"
  ["article_id"]=>
  string(4) "2577"
  [1]=>
  string(65) "Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon"
  ["article_title"]=>
  string(65) "Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon"
  [2]=>
  string(150) "The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as th"
  ["short_description"]=>
  string(150) "The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as th"
  [3]=>
  string(545) "
The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as the expiration of the waiting 
&#nl
The post Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(545) "
The all-cash deal between Catalent and Paragon, which was signed in April 2019, was completed after meeting of customary closing conditions such as the expiration of the waiting 
&#nl
The post Catalent wraps up $1.2bn acquisition of gene therapy CDMO Paragon appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/catalent-acquires-cdmo-paragon/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/catalent-acquires-cdmo-paragon/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:59"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}
                    

array(40) {
  [0]=>
  string(4) "2576"
  ["article_id"]=>
  string(4) "2576"
  [1]=>
  string(82) "SpringWorks Therapeutics initiates phase 3 trial of Nirogacestat in desmoid tumors"
  ["article_title"]=>
  string(82) "SpringWorks Therapeutics initiates phase 3 trial of Nirogacestat in desmoid tumors"
  [2]=>
  string(150) "Desmoid tumors are rare and often debilitating and disfiguring soft-tissue tumors that can aggressively invade surrounding healthy tissues, including "
  ["short_description"]=>
  string(150) "Desmoid tumors are rare and often debilitating and disfiguring soft-tissue tumors that can aggressively invade surrounding healthy tissues, including "
  [3]=>
  string(656) "
Desmoid tumors are rare and often debilitating and disfiguring soft-tissue tumors that can aggressively invade surrounding healthy tissues, including joints, muscles, blood vessels, nerves and internal organs. Depending 
&#nl
The post SpringWorks Therapeutics initiates phase 3 trial of Nirogacestat in desmoid tumors appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(656) "
Desmoid tumors are rare and often debilitating and disfiguring soft-tissue tumors that can aggressively invade surrounding healthy tissues, including joints, muscles, blood vessels, nerves and internal organs. Depending 
&#nl
The post SpringWorks Therapeutics initiates phase 3 trial of Nirogacestat in desmoid tumors appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(135) "https://www.pharmaceutical-business-review.com/news/springworks-therapeutics-initiates-phase-3-trial-of-nirogacestat-in-desmoid-tumors/"
  ["blog_url"]=>
  string(135) "https://www.pharmaceutical-business-review.com/news/springworks-therapeutics-initiates-phase-3-trial-of-nirogacestat-in-desmoid-tumors/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-05-23 14:23:59"
  ["create_at"]=>
  string(19) "2019-05-23 14:23:59"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}